An interventional study of CARES Intervention in Lung Cancer, Head and Neck Cancer and Thyroid Cancer, sponsored by University of Colorado, Denver. Recruiting at 14 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Lung Neoplasms by University of Colorado, Denver — 4 open to participants now, 8 under way, none of them phase 3. Lung Neoplasms · University of Colorado, Denver.
Among the 20 studies in Lung Neoplasms by University of Colorado, Denver, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2022, is one of 9 with no phase, and was the 18th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →4 of the 20 studies in Lung Neoplasms by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 18–85
University of Colorado, Denver · Sites in United States
Ages 18–85
University of Colorado, Denver · Sites in United States
Ages 21–90
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6
First in 1993; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 111 across the 16 interventional studies, 600 across the 4 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
1 of the studies in Lung Neoplasms by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04916990University of Colorado, DenverImproving Care for Rural Patients With Solid Tumors | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Lung Neoplasms by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cervical, breast, bladder, colon, and rectal cancers) in rural patients.
This is a randomized study. 320 participants will be enrolled to the CARES intervention or usual care arms. All participants will complete surveys to assess Quality of Care and Patient Reported outcomes at baseline, 3 months and 6 months. The CARES intervention will include a maximum of 10 navigation and 10 counseling sessions delivered over approximately a 6- month period delivered by oncology nurse navigators and master's level counselors. Sessions will be scheduled to correspond with key transition points during treatment and may be held in person, virtually, or by phone. Patients enrolled to the usual care arm will receive a standardized list of resources. Participation will last 6 months.
Inclusion Criteria Assessed During Screening:
Diagnosed with BLC using malignant neoplasm of ICD-O codes: C67.9 and other bladder cancer varients.
Inclusion Criteria Confirmed via Baseline Survey:
Rural and medically underserved, defined as meeting the following criteria:
Exclusion Criteria Assessed During Screening:
Has already initiated curative treatment for the current episode of cancer.
Exclusion Criteria Assessed via Baseline Survey:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will complete surveys to assess Quality of Care and Patient Reported outcomes at baseline, 3 months and 6 months. The CARES intervention will include a maximum of 10 navigation and 10 counseling sessions delivered over approximately a 6- month period delivered by oncology nurse navigators and master's level counselors. Sessions will be scheduled to correspond with key transition points during treatment and may be held in person, virtually, or by phone.
Behavioral: CARES Intervention
All participants will complete surveys to assess Quality of Care and Patient Reported Outcomes. Patients will receive a standardized list of resources.
Nurse navigators and masters levels counselors will meet with participants up to 10 times each (10 navigation and 10 counseling) over a 6 month period. The number of sessions will be determined by the length of the patient's treatment. The timing of each session will be guided by a regular assessment to reduce the time from diagnosis to initiation of treatment and the time between subsequent treatments. Sessions will occur at key transition points during treatment to target the factors associated with treatment delays, reduced Quality of Care and poor Patient Reported Outcomes
Time to care
Number of days from diagnosis to treatment initiation and number of days from treatment initiation to treatment completion
Time frame: From study start to study end (6 months)
Quality of Care
Use Quality of Care (QOC) questionnaire to determine if CARES intervention results in favorable QOC experience
Time frame: From study start to study end (6 months)
Patient Reported Outcomes
Use Patient Reported Outcomes (PRO) questionnaire to determine if CARES intervention results in improvements in distress, adaptive coping, and tobacco use
Time frame: From study start to study end (6 months)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Jan 2027, 52 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 52 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →